Edgewise Therapeutics (EWTX) executive Russell sold 1,551 shares for $25.5K at $16.45
Insider transactions reported
Alan J Russell (Chief Scientific Officer at Edgewise Therapeutics Inc., EWTX) reported that they sold 1,551 shares for $25.5K at $16.45, and acquired 5,209 shares between May 1, 2025 and May 2, 2025. After these transactions the filing shows 18,521 shares held directly.
- Reporting person
- Russell Alan J
- Role
- Chief Scientific Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| May 1, 2025 | Exercise or conversion of a derivative (M) | Common Stock | +5,209 | - | - | 20,072 direct |
| May 2, 2025 | Open-market sale (S) | Common Stock1, 2 | -1,551 | $16.45 | $25.5K | 18,521 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| May 1, 2025 | Exercise or conversion of a derivative (M) | Restricted Stock UnitsOn 5,209 Common Stock | -5,209 | - | - | 0 direct |
Holdings before and after
- Common Stock: 14,863 to 18,521 direct
- Restricted Stock Units: 5,209 to 0 direct
Footnotes from the filing
- 1. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person.
- 2. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $16.07 to $16.84, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Russell report in this EWTX Form 4?
Alan J Russell (Chief Scientific Officer at Edgewise Therapeutics Inc., EWTX) reported that they sold 1,551 shares for $25.5K at $16.45, and acquired 5,209 shares between May 1, 2025 and May 2, 2025. After these transactions the filing shows 18,521 shares held directly.
How many EWTX shares does Russell hold after this filing?
The filing shows 18,521 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this EWTX insider sale made under a 10b5-1 plan?
The filing's footnotes do not mention a Rule 10b5-1 trading plan.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for EWTX
Earlier insider filings at EWTX
- May 8, 2025General Counsel Moore John R converted options into 5,209 shares and sold $31,757 worth of shares (1,930 units at $16.45), increasing direct ownership by 101% to 6,531 units (SEC Form 4)
- May 8, 2025President and CEO Koch Kevin converted options into 10,417 shares and sold $70,358 worth of shares (4,276 units at $16.45), increasing direct ownership by 42% to 20,619 units (SEC Form 4)
- May 8, 2025CMO Donovan Joanne M. converted options into 10,417 shares and sold $85,348 worth of shares (5,187 units at $16.45), increasing direct ownership by 32% to 21,588 units (SEC Form 4)
- May 8, 2025Chief Business Officer Derakhshan Behrad converted options into 5,209 shares and sold $27,824 worth of shares (1,691 units at $16.45), increasing direct ownership by 21% to 20,355 units (SEC Form 4)
- May 8, 2025Chief Financial Officer Carruthers R Michael converted options into 5,209 shares and sold $21,621 worth of shares (1,314 units at $16.45), increasing direct ownership by 5% to 81,014 units (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Follow EWTX and get a push notification the moment its next story breaks.